# Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes

> **NCT01647542** · PHASE3 · TERMINATED · sponsor: **Takeda** · enrollment: 393 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** TAK-875
- **DRUG:** TAK-875 Placebo

## Key facts

- **NCT ID:** NCT01647542
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2014-02
- **Final completion:** 2014-03
- **Target enrollment:** 393 (ACTUAL)
- **Why stopped:** Due to potential concerns about liver safety (See Detailed Description)
- **Last updated:** 2015-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01647542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01647542, "Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01647542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*